Lupin Announces the Approval and Launch of Brivaracetam Oral Solution in the United States

Lupin Secures USFDA Nod for Epilepsy Drug Brivaracetam in US

Mumbai: Mumbai-based pharmaceutical major Lupin Limited has received approval from the US Food and Drug Administration (USFDA) for its Brivaracetam Oral Solution 10 mg/mL and has launched the product...

Lupin gets USFDA nod for generic drug to treat seizures

Lupin receives USFDA approval for generic Brivaracetam Oral Solution to treat seizures, initiating its U.S. market launch.

Lupin shares rise 1.5% as firm gets USFDA nod for generic drug

The Mumbai-based firm has received a nod from the USFDA for its abbreviated new drug application for Brivaracetam Oral Solution (10 mg/mL)

Lupin Announces the Approval and Launch of Brivaracetam Oral Solution in the United States

MUMBAI, India and NAPLES, Fla., Feb. 24, 2026 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval from the U.S. FDA for its Abbreviated New Drug…

Lupin receives US FDA approval for Brivaracetam Oral Solution 10 mg/mL

Lupin has received approval from the U.S. Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Brivaracetam Oral Solution 10 mg/mL. Brivaracetam is the bioequivalent to Briviact Oral Solution, 10 mg/mL, of UCB, Inc., and is indicated for the treatment of partial-onset seizures in patients one month of age and older. Following the approval, the company initiated the launch of Brivaracetam Oral Solution in the …